Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Optimizing Time-to-Treatment to achieve durable biochemical disease control after surgery in prostate cancer - A multi-institutional cohort study.

Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov 9. pii: cebp.0812.2018. doi: 10.1158/1055-9965.EPI-18-0812. [Epub ahead of print]

PMID:
30413401
2.

Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.

Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Noris Chiorda B, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2017 Jun;71(6):886-893. doi: 10.1016/j.eururo.2016.07.028. Epub 2016 Jul 30.

PMID:
27484843
3.

Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy.

Zhang GM, Zhu Y, Ma XC, Qin XJ, Wan FN, Dai B, Sun LJ, Ye DW.

Medicine (Baltimore). 2015 Oct;94(41):e1473. doi: 10.1097/MD.0000000000001473.

4.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
5.

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.

JAMA. 2005 Jul 27;294(4):433-9.

PMID:
16046649
6.

Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.

Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

World J Urol. 2016 Oct;34(10):1357-66. doi: 10.1007/s00345-016-1781-y. Epub 2016 Feb 12.

PMID:
26873596
7.

Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial.

Bosland MC, Kato I, Zeleniuch-Jacquotte A, Schmoll J, Enk Rueter E, Melamed J, Kong MX, Macias V, Kajdacsy-Balla A, Lumey LH, Xie H, Gao W, Walden P, Lepor H, Taneja SS, Randolph C, Schlicht MJ, Meserve-Watanabe H, Deaton RJ, Davies JA.

JAMA. 2013 Jul 10;310(2):170-8. doi: 10.1001/jama.2013.7842.

8.

Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.

Abdel Raheem A, Chang KD, Alenzi MJ, Ham WS, Han WK, Choi YD, Rha KH.

Int J Urol. 2018 Dec;25(12):1006-1014. doi: 10.1111/iju.13808. Epub 2018 Oct 1.

PMID:
30276864
9.

Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.

Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, Briganti A, Rouprêt M, Loidl W, Trinh QD, Bachmann A, Pourmand G.

Eur Urol. 2015 Dec;68(6):949-56. doi: 10.1016/j.eururo.2015.05.038. Epub 2015 Jun 3.

PMID:
26050111
11.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
12.

Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Nagao K, Matsuyama H, Matsumoto H, Nasu T, Yamamoto M, Kamiryo Y, Baba Y, Suga A, Tei Y, Yoshihiro S, Aoki A, Shimabukuro T, Joko K, Sakano S, Takai K, Yamaguchi S, Akao J, Kitahara S; Yamaguchi Uro-Oncology Group.

Int J Clin Oncol. 2018 Aug;23(4):757-764. doi: 10.1007/s10147-018-1272-9. Epub 2018 Mar 27.

13.

Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.

Beauval JB, Ploussard G, Cabarrou B, Roumiguié M, Ouzzane A, Gas J, Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X, Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of the Association of French Urology.

World J Urol. 2017 Aug;35(8):1191-1197. doi: 10.1007/s00345-016-1979-z. Epub 2016 Dec 16.

PMID:
27987030
14.

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC.

JAMA. 2008 Jun 18;299(23):2760-9. doi: 10.1001/jama.299.23.2760.

15.

The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.

Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

Eur Urol. 2015 Feb;67(2):342-6. doi: 10.1016/j.eururo.2014.06.015. Epub 2014 Jun 23.

PMID:
24968968
16.

Postoperative early ultrasensitive prostate-specific antigen identifies patients at risk for biochemical recurrence in margin positive prostate cancers: a single-center study.

Hatano K, Okusa T, Ishizuya Y, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K.

Jpn J Clin Oncol. 2017 Jan;47(1):74-79. doi: 10.1093/jjco/hyw150. Epub 2016 Oct 12.

PMID:
27733509
17.

Obesity and long-term survival after radical prostatectomy.

Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

J Urol. 2014 Oct;192(4):1100-4. doi: 10.1016/j.juro.2014.04.086. Epub 2014 Apr 21.

PMID:
24769031
18.

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.

Taguchi S, Fukuhara H, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y.

BMC Urol. 2014 Oct 16;14:81. doi: 10.1186/1471-2490-14-81.

19.

L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.

Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C.

BJU Int. 2012 Sep;110(6 Pt B):E267-73. doi: 10.1111/j.1464-410X.2012.11152.x. Epub 2012 May 9.

20.

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C.

Prostate. 2017 Apr;77(5):549-556. doi: 10.1002/pros.23296. Epub 2017 Jan 17.

Supplemental Content

Support Center